Innovent Biologics

Our new ESG website is live! At Innovent, our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals drives us to integrate ESG principles into every aspect of our value chain. We are dedicated to ensuring the highest quality in our products, while also caring for our people and the environment. Discover more about our commitment to Environmental, Social and Governance (ESG) initiatives on our newly launched website: https://lnkd.in/gzQrv-gW #ESG #Sustainability #Healthcare #InnoventBiologics

We are thrilled to announce that Innovent has been recognized in Universum's "2024 China's Most Attractive Employers Rankings"! 🏅 10th Position as the Most Attractive Employer for natural science students 🏅 19th Position as the Most Attractive Employer for health/medicine students 🏅 Top 100 Most Attractive Employers for engineering students This achievement highlights our commitment to innovation, mentorship, excellence in cutting-edge research and therapies, strong corporate social responsibility and our inspiring mission and vision. We're grateful to our incredible team and community for making this possible. Together, we are creating a supportive workplace, prioritizing employee wellness, and inspiring our team to make a positive difference in healthcare. #InnoventBiologics #Healthcare #Universum2024

Our team had the incredible opportunity to give an oral presentation at ESMO GI in Munich. We shared the latest Phase 1 clinical data of our innovative anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ AC). The results demonstrate that IBI343 has promising efficacy and a favorable safety profile in patients with G/GEJ AC whose tumors express CLDN18.2. We’re proud to be pushing the boundaries of cancer treatment and improving patient outcomes. https://lnkd.in/gujfiyyv #ESMOGI2024 #ClinicalTrials #InnoventBiologics #Oncology

At #ADA2024 and during our recent investor call, Innovent presented the promising results of the GLORY-1 Phase 3 clinical trial for the GLP-1R/GCGR dual agonist mazdutide, along with updates on our general biomedicine pipeline. See the exciting results here:https://lnkd.in/gPrQhh8S

We're especially thrilled to share the GLORY-1 Phase 3 study results of liver fat content in Chinese adults with overweight or obesity at the #ADA Scientific Sessions 2024. This clinical trial of mazdutide brings us closer to offering improved treatment options for those with metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD). https://lnkd.in/gdXTAxKp

Exciting news from the ADA Scientific Sessions 2024! Our team presented the key results from the first Phase 3 clinical trial of the GLP-1R/GCGR dual agonist mazdutide in Chinese adults with overweight or obesity, where GLORY-1 met all primary and key secondary endpoints, showcasing robust weight loss, reduced liver fat content, and improvements in multiple cardiometabolic risk factors. https://lnkd.in/gtzSRyC6 #ADA2024 #InnoventBiologics

We’re glad to share the positive data from our oncology pipeline update at today's investor meeting. Encouraged by the progress we're making in cancer treatment. https://lnkd.in/gtE7VKYu #Oncology #innoventbiologics

 We are pleased to invite investors, analysts and stakeholders to participate in our conference call on June 25, highlighting clinical updates from our general biomedicine product line. Registration required at the link below. https://lnkd.in/gcgmSBv6

Innovent is presenting clinical data on our first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein (IBI363) at the 2024 ESMO Virtual Plenary, June 13-14. Read below about this antibody's promising safety signals, its broad anti-tumor activity and its applicability across tumor types. #ESMOVirtualPlenary #oncology #InnoventBiologics https://lnkd.in/guaqFQmN

We're pleased to announce that Innovent's TOPO1i anti-CLDN18.2 ADC (IBI343) has received Fast Track Designation from the FDA for advanced pancreatic cancer. We're thrilled to be closer to offering an innovative treatment option for one of the most challenging cancers to treat. https://lnkd.in/eZ9eHrkA